{"id":328242,"date":"2021-08-21T14:00:00","date_gmt":"2021-08-21T12:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/tirzepatide-convinces-with-superior-hba1c-and-weight-reduction\/"},"modified":"2021-08-21T14:00:00","modified_gmt":"2021-08-21T12:00:00","slug":"tirzepatide-convinces-with-superior-hba1c-and-weight-reduction","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/tirzepatide-convinces-with-superior-hba1c-and-weight-reduction\/","title":{"rendered":"Tirzepatide convinces with superior HbA1c and weight reduction"},"content":{"rendered":"<p><strong>The dual GLP-1\/GIP receptor agonist tirzepatide is currently being evaluated in Phase III clinical trials. In adult type 2 diabetics at increased cardiovascular risk, tirzepatide resulted in superior HbA1c and body weight reductions compared with titrated insulin glargine.<\/strong><\/p>\n<p><!--more--><\/p>\n<p>URPASS-4 is an open-label global study comparing the safety and efficacy of three doses of tirzepatide (5&nbsp;mg, 10&nbsp;mg and 15&nbsp;mg) with titrated insulin glargine in more than 2000 people with type 2 diabetes who are at increased cardiovascular risk and are being treated with one to three oral antihyperglycemic agents (metformin, a sulfonylurea, or an SGLT-2 inhibitor).<\/p>\n<p>Study participants had a mean diabetes duration of 11.8&nbsp;years, baseline HbA1c at 8.52%, and body weight at baseline of 90.3&nbsp;kg. Over 85% of participants had a history of cardiovascular events. At the highest tirzepatide dose, 90.7% of participants achieved an HbA1c of less than 7% &#8211; the American Diabetes Association&#8217;s recommended target for diabetics &#8211; after 52&nbsp;weeks, and 43.1% achieved an HbA1c of less than 5.7%. This corresponds to an HbA1c reduction of 2.58%. During the same period, an average body weight reduction of 11.7&nbsp;kg (13.0%) was achieved.<\/p>\n<p>In the insulin glargine group, insulin dose was titrated according to a treat-to-target algorithm, with the goal of maintaining fasting blood glucose below 100&nbsp;mg\/dl. The starting dose of insulin glargine was 10&nbsp;units per day, and the mean dose of insulin glargine after 52&nbsp;weeks was 43&nbsp;units per day. In those treated with insulin glargine, a 1.44% reduction in HbA1c and an average weight loss of 1.9&nbsp;kg were achieved after 52&nbsp;weeks.<\/p>\n<p>The overall safety profile of tirzepatide in this patient population was comparable to the glucagon-like peptide-1 (GLP-1) receptor agonist class. Gastrointestinal adverse events were the most commonly reported adverse events, usually occurring during the escalation phase and then decreasing over time.<\/p>\n<p>&nbsp;<\/p>\n<p><em>Source: &#8220;Lilly&#8217;s tirzepatide achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS-4 trial,&#8221; 05\/20\/2021.<\/em><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><em>CARDIOVASC 2021; 20(2): 33<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The dual GLP-1\/GIP receptor agonist tirzepatide is currently being evaluated in Phase III clinical trials. In adult type 2 diabetics at increased cardiovascular risk, tirzepatide resulted in superior HbA1c and&hellip;<\/p>\n","protected":false},"author":7,"featured_media":109539,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Diabetes Therapy","footnotes":""},"category":[11359,11384,11530,11323,11548,11503],"tags":[],"powerkit_post_featured":[],"class_list":["post-328242","post","type-post","status-publish","format-standard","has-post-thumbnail","category-cardiology","category-endocrinology-and-diabetology","category-market-medicine","category-partner-content-en","category-rx-en","category-studies","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-20 09:01:11","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":328253,"slug":"le-tirazepatide-se-distingue-par-une-reduction-superieure-de-lhba1c-et-du-poids","post_title":"Le tiraz\u00e9patide se distingue par une r\u00e9duction sup\u00e9rieure de l'HbA1c et du poids","href":"https:\/\/medizinonline.com\/fr\/le-tirazepatide-se-distingue-par-une-reduction-superieure-de-lhba1c-et-du-poids\/"},"it_IT":{"locale":"it_IT","id":328257,"slug":"la-tirzepatide-convince-con-una-riduzione-superiore-di-hba1c-e-di-peso","post_title":"La tirzepatide convince con una riduzione superiore di HbA1c e di peso","href":"https:\/\/medizinonline.com\/it\/la-tirzepatide-convince-con-una-riduzione-superiore-di-hba1c-e-di-peso\/"},"pt_PT":{"locale":"pt_PT","id":328262,"slug":"tirzepatide-convence-com-hba1c-superior-e-reducao-de-peso","post_title":"Tirzepatide convence com HbA1c superior e redu\u00e7\u00e3o de peso","href":"https:\/\/medizinonline.com\/pt-pt\/tirzepatide-convence-com-hba1c-superior-e-reducao-de-peso\/"},"es_ES":{"locale":"es_ES","id":328267,"slug":"la-tirzepatida-convence-con-una-reduccion-superior-de-la-hba1c-y-del-peso","post_title":"La tirzepatida convence con una reducci\u00f3n superior de la HbA1c y del peso","href":"https:\/\/medizinonline.com\/es\/la-tirzepatida-convence-con-una-reduccion-superior-de-la-hba1c-y-del-peso\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/328242","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=328242"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/328242\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/109539"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=328242"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=328242"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=328242"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=328242"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}